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Abstract
Background: GH therapy requires daily injections over many years and compliance can be difficult to sustain. As growth
hormone (GH) is expensive, non-compliance is likely to lead to suboptimal growth, at considerable cost. Thus, we aimed to
assess the compliance rate of children and adolescents with GH treatment in New Zealand.
Methods: This was a national survey of GH compliance, in which all children receiving government-funded GH for a four-
month interval were included. Compliance was defined as $85% adherence (no more than one missed dose a week on
average) to prescribed treatment. Compliance was determined based on two parameters: either the number of GH vials
requested (GHreq) by the family or the number of empty GH vials returned (GHret). Data are presented as mean 6 SEM.
Findings: 177 patients were receiving GH in the study period, aged 12.160.6 years. The rate of returned vials, but not
number of vials requested, was positively associated with HVSDS (p,0.05), such that patients with good compliance had
significantly greater linear growth over the study period (p,0.05). GHret was therefore used for subsequent analyses. 66%
of patients were non-compliant, and this outcome was not affected by sex, age or clinical diagnosis. However, Maori
ethnicity was associated with a lower rate of compliance.
Interpretation: An objective assessment of compliance such as returned vials is much more reliable than compliance based
on parental or patient based information. Non-compliance with GH treatment is common, and associated with reduced
linear growth. Non-compliance should be considered in all patients with apparently suboptimal response to GH treatment.
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Introduction
Non-compliance with prescribed drug treatments is widespread
[1]. Key factors include discomfort (e.g. associated with daily
injections) [2], long-term treatment [3], complexity of treatment
regimens, age, individual and family dynamics, as well as patient
or family’s understanding of treatment benefits and consequences
of non-compliance [3,4]. These principles suggest that children
administered growth hormone (GH) as a daily subcutaneous
injection for many years are at risk of treatment non-compliance.
GH treatment is very expensive; the annual cost for a 30 kg child
has been estimated as US$ 15,000 to US$ 20,000 per annum,
while the annual costs of treating adolescents to maximize adult
height can reach US$ 50,000 [5]. Thus, non-compliance with
treatment must lead to appreciable waste of funding; it is
presumed that it would also impair long-term linear growth
[6,7], but there are few objective data.
In this study we examined compliance with GH treatment and
its effect on linear growth over a single four-month period in a
complete national cohort of New Zealand children and adoles-
cents. In view of the reliance of previous studies on self-report or
prescription data [6–11], we contrasted a caregiver-reported
measure of GH utilisation with an objective measure (number of
GH vials returned during the interval).
Materials and Methods
Review with the Multiregion Ethics Committee (Wellington,
New Zealand) determined that ethics approval of this compre-
hensive audit was not required.
This study was an unbiased, anonymized national survey of GH
compliance in all New Zealand children and adolescents receiving
publically-funded GH in a single four-month interval in 2007. All
patients receive monthly allocations of GH based upon surface
area dosing. Each month, the caregivers of the patients are
contacted by phone to determine how many residual vials of GH
the family have, and thus how many vials are required for the
coming month (GHreq). For the duration of this review, caregivers
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hormone administrator each month, using a prepaid courier bag
sent directly to the family (GHret). Parents were actively
encouraged, but could not be mandated to return all empty vials.
To ensure that no empty GH vials were left over from periods
preceding the study, empty vials were requested starting the month
before the study.
Compliance was evaluated in two ways: number of GH vials
required each month (GHreq; based on verbal self-report by the
patient’s caregivers) and number of used GH vials returned
(GHret), with both expressed as a percentage of the number of
vials prescribed for each patient. Based on the known doses of GH
prescribed, no patients should have used less than one vial of GH
over the 4-month duration of this investigation, and therefore
patients who returned no vials over the study period were excluded
from analysis.
Growth data are routinely obtained every 6 months for all
patients. Growth rates were calculated for the 6–8 month-period
that encompassed the interval of this audit. Changes in height
were recorded and converted to height velocity standard deviation
scores (HVSDS) to control for sex and age differences. For the
purposes of analysis, compliance was defined as 85% or better
adherence to the prescribed treatment, equivalent to an average of
one missed dose a week. Patients were divided into three groups
according to their rate of compliance: High compliance (missed
#1 dose a week on average), Medium (missed .1 and ,3 doses/
week), and Low (missed $3 doses/week).
The association between GHret and GHreq to HVSDS was
assessed using non-parametric Spearman’s rank correlations.
HVSDS was compared across compliance groups using a general
linear regression model (GLM), which also included as factors
diagnosis (i.e. KIGS code 1, 2 or 3) and an interaction between
diagnosis and compliance group, in order to account for
differential growth responses to GH treatment. Subsequently,
the effects of age, sex, ethnicity, area of residence (cities (.100,000
inhabitants) vs. towns and rural areas) and diagnosis on GH
compliance for each subject were examined. A GLM was used
with compliance rate as the response, and sex, ethnicity, diagnosis
and area of residence as independent variables, and age included
as covariate. A binary logistic linear regression was then adopted
to determine if any of the above factors had an effect on whether a
patient was compliant or not. Posthoc pairwise comparisons were
carried out using Tukey’s simultaneous tests. All analyses were
carried out in Minitab (Minitab v.15, Pennsylvania State
University, USA), with Johnson transformation as required to
stabilize the variance. Data are presented as mean 6 SEM.
Results
175 patients received GH in the 4 month interval of the analysis
and were 12.160.6 years old with 48% males. Diagnoses included
GH deficiency (57%), Turner Syndrome (27%), idiopathic short
stature (7%), small for gestational age (6%), Prader Willi
Syndrome (3%) and other (6%). The caregivers identified the
children as European & other (75%), Maori (15%), Asian (7%),
and Pacific Islander (4%). 35% of patients resided in Auckland,
34% elsewhere in the North Island, and 22% in the South Island.
A total of 25 patients failed to return a single vial during the
study period, and were excluded from the GHret analysis. The
overall estimated rate of non-compliance (i.e. patients missing
more than one injection per week) was 66% (73/110) according to
GHret and 34% (59/172) according to GHreq. HVSDS was
positively correlated with the rate of returned vials (r=0.20;
p,0.05) but not with GHreq. Further, average linear growth of
patients increased as GHret compliance levels increased, and
missing more than one dose a week significantly reduced linear
growth (p,0.01) (Fig. 1), whereas GHreq showed no association
with growth (p=0.83). GHret was therefore used for subsequent
analyses. Finally, patients with organic GH-deficiency tended to
grow faster than subjects with other causes of short stature
(HVSDS 2.3260.60 vs 0.9360.38; p,0.06).
Compliance rates were not associated with age, gender,
diagnosis or area of residence. However, Maori patients missed
nearly one extra GH dose a week on average in comparison to
other ethnic groups (p,0.05).
Discussion
This national survey indicates that non-compliance with GH
treatment is very common in New Zealand, based on objective
data, in a setting where there is regular, direct contact with
caregivers and no personal financial constraints on GH uptake.
Further, the two thirds of patients who on average missed one or
more doses of GH each week showed significantly reduced linear
growth compared with compliant patients. To our knowledge our
study is the first to provide robust evidence that non-compliance is
a common cause of suboptimal response to GH treatment in
children and adolescents.
The use of returned GH vials in this study provided an objective
measure of compliance in a complete population of children and
adolescents receiving GH. A higher GHret should reflect the
number of vials used in the previous month and thus denote
greater compliance. A potential limitation is that return of used
GH vials was not a mandatory pre-condition to receive new vials.
Therefore, although GHret was an objective measure in contrast
with caregiver-reported GHreq, vials might have been broken,
lost, or the empty vials simply not sent back to the programme, so
that GHret could have underestimated compliance. Nonetheless,
the strong correlation with patient growth suggests that this
approach still provided a reasonably valid measure of compliance.
An alternative approach would be the use of electronic injection
devices with a dosage counter to accurately assess patient
compliance. Such devices are available but are limited by cost,
complexity and robustness. This may become practical for
Figure 1. Height velocity standard deviation scores (HVSDS)
over 6–8 months according to the level of compliance with GH
treatment: High (n=30) missed #1 dose/week, Medium (n=51)
missed .1 and ,3 doses/week, and Low (n=29) missed $3
doses/week. Data are mean 6 SEM. **p,0.01, ***p,0.001 vs High.
doi:10.1371/journal.pone.0016223.g001
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and cheaper electronic injection devices.
In contrast, in the present study compliance estimated by
caregiver-report showed no correlation with growth response. This
method is broadly similar to retrospective patient questionnaires or
GH prescription data used in previous studies [6–11]. Although a
higher GHreq should also indicate better compliance, caregivers
may not admit to having failed to use the appropriate amount of
GH, and therefore GHreq is likely to overestimate compliance. In
other conditions, consistent with our findings, such studies are
reported to overestimate adherence to drug treatment, whether
due to forgetfulness, embarrassment or fear of recrimination [12].
Our study indicates that patient and/or parent reported
compliance (GHreq) is an unreliable measure of GH treatment
compliance. This is consistent with the finding that in children
requiring antibiotic prophylaxis after urinary tract infection, 97%
of parents reported giving antibiotics every day, but only 69% of
urine samples were positive [13]. Understanding compliance is
important as clinicians are generally unable to accurately predict
treatment adherence [14], and non-compliance can mislead
medical practitioners regarding the efficacy of treatment and lead
to invasive testing for other causes of poor growth.
Further, compliance is not an end in itself. Only one previous
study (reported solely in abstract form) has examined the
quantitative relationship between compliance and linear growth
[7]. The present study demonstrates for the first time that missing
more than one GH dose a week can compromise longitudinal
growth. Importantly, we showed a continuous relationship
between missed doses and growth. In other words there was no
apparent threshold effect, and missing more than one GH dose
each week would likely affect growth.
There are few validated strategies to improve adherence to GH
treatment. Reduction of injection frequency with depot GH would
likely improve compliance, as seen with other depot injectable
therapies such as GnRH agonists [15], but is not possible at
present. Since the pain of injections has been reported to be a
concern [2], strategies to reduce pain such as automatic pens or
use of finer injection needles may be beneficial. Oyarzabal et al
showed in a multicentre survey that users of automatic pens were
significantly more compliant with GH treatment than those using
conventional syringes [8]. Although there are no data on GH, in
other settings daily drug reminder charts [16], financial incentives
[17,18], provision of enhanced support and education for patients
and their families on the benefits of therapy and consequences of
non-compliance may improve adherence rates [19]. However,
parents receive relatively consistent support and education in New
Zealand, both centrally, at the time of induction and around GH
deliveries, and from paediatricians and clinic nurses, and thus
improved education is unlikely to suffice.
The finding of a higher incidence of non-compliance among the
indigenous Maori community is of concern. Maori children have a
higher burden of many diseases as well as higher rates of
complications during treatment of other chronic illnesses such as
diabetes [20,21]. Previous authors have acknowledged that Maori
also display poorer compliance with medical treatments [21], so
that developing culturally safe ways to improve adherence to long-
term treatment regimens will be critical to improving outcomes in
vulnerable groups [20].
In conclusion, the present study strongly suggests that poor-
compliance is one of the most common factors underlying
suboptimal growth during GH therapy, and should be actively
evaluated and managed before considering other illnesses that can
affect growth or partial GH resistance. It is critical to find ways to
improve families’ compliance with GH treatment.
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